First-in-humans, first-in-children use of MSCs as carriers for oncolytic virotherapy.

This strategy allows administering very high amount of oncolytic virus with minimum toxicities.

Pre-therapy T cell status and T effector responses were important aspects associated to the outcome.

The presence of MSCs in the medicine product may prevent antioncovirus immune responses.